Precision Biosciences Return on Equity

Precision Biosciences (DTIL) currently reports a ROE of -116.42%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore Precision Biosciences's ROE history and peer comparisons.

Precision Biosciences's ROE of -116.42% is lower than the Healthcare sector average of -100.59%. That is roughly 15.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Precision Biosciences's current -116.42% should be judged against Healthcare norms (sector average: -100.59%) and against DTIL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -116.42%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Precision Biosciences, and consider following DTIL for alerts when major investors trade the stock.

Precision Biosciences is classified in the Healthcare sector. On ROE, it currently shows -116.42% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DTIL with unrelated industries.